10094849An innovative urinary drainage system that could reduce NHS CAUTI treatment costs by 10% and increase quality-of-life for men suffering from chronic incontinenceClosedCollaborative R&DInnovate UKIngenion is a UK-based medical device SME with a core project team of Edward Cappabianca (project lead), Susan Finch (project manager), James Barnett (design engineer), Tim Maloney (commercial director) and Zia Mursaleen (finance manager). Urinary incontinence impacts physical and emotional health, causing humiliation and social issues. Frequent catheterisation increases the risk of catheter-associated urinary tract infections (CAUTIs), which can be fatal and cost the NHS £567.6M/year. CAUTIs represent 17.2% of all Health-Care Associated Infections (HCAIs), and HCAIs have been estimated to cost the NHS between £1.6-£5B/year (Canadian-Journal-of -Infection-Control,Sep2020). Long-term catheter users experience an average of 2.7 CAUTIs per year (Coloplast, 2023), with a cost of £3,500 per incident. Around 90,000 people in the UK live with long-term catheters, with over 4B catheters used worldwide annually. Some people try to manage incontinence by drinking less water, but this has been shown to worsen apparently unrelated conditions, such as dementia. To solve this unmet need, Ingenion is developing a revolutionary indwelling urinary drainage system (_**cym**active_ SealSoft) that eliminates the need for external bags or tubes. The _**cym**active_ SealSoft device for incontinence will provide male patients with normal fill/void cycles without any inconvenience or risk of CAUTIs. This innovation will have a significant impact on patients suffering from MS, Parkinson's, spinal cord injuries and spina bifida. Not only will it improve their quality of life, but it will also help increase their life expectancy by allowing them to remain active. The unique selling points of this device are its leak-proof design and patented magnetic valve technology, which ensures greater confidence and a potential economic benefit from a reduction in CAUTI treatment costs for the NHS by 10% of the HCAIs related to CAUTIs could be as much as £57M/year.